Eisai Co. Ltd. (ESAIY PINK) stock market data APIs
$7.4032
0.03(0.4%)
as of December 11, 2025
Try our APIs with
free plan!
Eisai Co. Ltd. Financial Data Overview
Price chart is built with
Anychart
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. The company offers Dayvigo, an orexin receptor antagonist for the treatment of insomnia; LEQEMBI, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody for Alzheimer's disease; Lenvima, an orally available multiple receptor tyrosine kinase inhibitor for the treatment of thyroid cancer and hepatocellular carcinoma, thymic carcinoma, renal cell carcinoma, and endometrial carcinoma; Fycompa, an anti-epileptic agent for primary generalized tonic-clonic seizures; and Halaven, a microtubule dynamics inhibitor for breast cancer and liposarcoma. It operates in Japan, China, the Americas, Europe, the Middle East, Africa, and East Asia Global South. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Prev. Close
7.4032
Open
7.4282
High
7.5111
Low
7.3936
52 wk Range
5.8688-9.1094
Market Cap
8 457 M
P/E Ratio
26.4107
Shares Outstanding
1 128 M
Revenue
804 390 M
EPS
36.03
Dividends (Yield)
0.0362
Beta
-0.271
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eisai Co. Ltd. data using free add-ons & libraries
Get Eisai Co. Ltd. Fundamental Data
Eisai Co. Ltd. Fundamental data includes:
- Net Revenue: 804 390 M
- EBITDA: 93 028 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eisai Co. Ltd. News
New
Leqembi included in China's commercial insurance innovative drug list
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innova...
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
Biogen Inc. TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: C...
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)?
In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet ...
Is Eisai Now an Opportunity After Mixed Signals from DCF and Earnings Valuation?
If you are wondering whether Eisai is quietly becoming a value opportunity or just a value trap, you are in the right place to unpack what the current share price is really implying. The stock has bee...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
